共病物质使用障碍患者门诊抑郁治疗质量
该回顾性队列研究纳入美国退伍军人健康管理局2017财年诊断为抑郁障碍的53034例患者,评估共病物质使用障碍与指南一致性抑郁治疗(药物和心理治疗)的关联。结果显示,共病物质使用障碍患者接受指南一致性抑郁治疗的概率在各指标上均更低,提示需通过临床医生干预和整合照护模式改善该人群的治疗质量。
要点
- 共病物质使用障碍患者接受指南一致性急性期抗抑郁治疗和持续治疗的概率分别低21%和26%。
- 共病物质使用障碍患者接受充分急性期心理治疗和持续心理治疗的概率分别低13%和19%。
- 应通过临床医生干预和整合照护模式改善共病物质使用障碍患者的抑郁治疗质量。
核心结论
- 尽管抑郁障碍存在有效治疗,共病物质使用障碍患者接受指南一致性抑郁治疗的可能性更低。
研究设计与样本
- 回顾性队列研究,纳入美国退伍军人健康管理局2017财年诊断为抑郁障碍的53034例患者,评估共病物质使用障碍与指南一致性抑郁治疗的关联,并调整人口学和临床特征。
主要发现
- 共病物质使用障碍患者接受指南一致性急性期抗抑郁治疗的比值比为0.79(95% CI=0.73, 0.84),持续治疗为0.74(95% CI=0.69, 0.79)。
- 共病物质使用障碍患者接受充分急性期心理治疗的比值比为0.87(95% CI=0.82, 0.91),持续心理治疗为0.81(95% CI=0.73, 0.89)。
关键数值与推荐
- 指南一致性抑郁治疗包括药物治疗和心理治疗,具体评估指标涉及急性期治疗和持续治疗。
临床怎么用
- 临床应关注共病物质使用障碍的抑郁患者,通过临床医生干预和整合照护模式提高其指南一致性治疗的可及性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Clinical practice guidelines recommend concurrent treatment of co-occurring depression and substance use disorders; however, the degree to which patients with substance use disorders receive guideline-concordant treatment for depression is unknown. The authors investigated the provision of guideline-concordant depression treatment to patients with and without substance use disorders in a large integrated health care system. METHODS: In a retrospective cohort study of 53,034 patients diagnosed with a depressive disorder in fiscal year 2017 in the U.S. Veterans Health Administration, the authors assessed the association of comorbid substance use disorders with guideline-concordant depression treatment, including both medication and psychotherapy, while adjusting for patient demographic and clinical characteristics. RESULTS: Guideline-concordant depression treatment was lower across metrics for patients with co-occurring depression and substance use disorders compared to those without substance use disorders. Consistent findings emerged in covariate-adjusted models of antidepressant treatment, such that patients with substance use disorders had 21% lower odds of guideline-concordant acute treatment (adjusted odds ratio=0.79, 95% CI=0.73, 0.84) and 26% lower odds of continuation of treatment (adjusted odds ratio=0.74, 95% CI=0.69, 0.79). With regard to psychotherapy, patients with co-occurring depression and substance use disorders had 13% lower odds (adjusted odds ratio=0.87, 95% CI=0.82, 0.91) of adequate acute-phase treatment and 19% lower odds (adjusted odds ratio=0.81; 95% CI=0.73, 0.89) of psychotherapy continuation. CONCLUSIONS: Despite the availability of effective treatments for depression, patients with co-occurring substance use disorders are less likely to receive guideline-concordant depression treatment. Efforts to improve the provision of care to those with co-occurring substance use disorders should focus on clinician-based interventions and use of integrated care models to improve the quality of depression treatment.
引用
- Coughlin LN, Pfeiffer P, Ganoczy D, et al. Quality of Outpatient Depression Treatment in Patients With Comorbid Substance Use Disorder. Am J Psychiatry. 2020. PMID: 33115247. doi:10.1176/appi.ajp.2020.20040454
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。